The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human
1 other identifier
observational
40
1 country
1
Brief Summary
This is an observation study to investigate the molecular mechanism of NKG2C+NK cell expansion after HCMV infection
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2020
CompletedFirst Submitted
Initial submission to the registry
March 4, 2020
CompletedFirst Posted
Study publicly available on registry
March 6, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2021
CompletedOctober 1, 2020
September 1, 2020
1 year
March 4, 2020
September 30, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
CMV viremia
CMV-DNA\>1.0x10\^3 cpies/mL
2 moths post-transplantation
Eligibility Criteria
AML or MDS or CML or ALL undergoing haploidentical stem cells transplantation AND the healthy donors.
You may qualify if:
- AML or MDS or CML or ALL undergoing haploidentical stem cells transplantation
- No severe organ dysfunction or failure
- Subjects must be capable of, and willing to provide written informed consent to participate in the study. Subjects unable to provide written informed consent by themselves may be consented through their legal representative.
You may not qualify if:
- Participation in another industry-sponsored clinical study where treatment for CMV is already specified by the study protocol.
- Patients received other adoptive immunotherapy such as donor lymphocyte infusion (DLI), Epstein-Barr virus (EBV)-specific T cells and so on.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Peking University Institute of Hematology
Beijing, Beijing Municipality, 100044, China
Biospecimen
peripheral blood
Study Officials
- STUDY CHAIR
Xiaojun Huang, M.D., PhD
Peking University People's Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of Peking University Institute of Hematology
Study Record Dates
First Submitted
March 4, 2020
First Posted
March 6, 2020
Study Start
January 1, 2020
Primary Completion
December 31, 2020
Study Completion
December 31, 2021
Last Updated
October 1, 2020
Record last verified: 2020-09